Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared wit
Go back to Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared wit| (NASDAQ: ELDN) | Delayed: 2.94 -0.08 (2.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.02 | 52 Week High | $ | |||
| Open | $3.02 | 52 Week Low | $ | |||
| Day High | $3.03 | P/E | N/A | |||
| Day Low | $2.92 | EPS | $ | |||
| Volume | 632,376 | |||||
